Comparison of the Long-Acting GnRH Agonist Follicular Protocol with the GnRH Antagonist Protocol in Women Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis.
Assisted reproductive technology
Controlled ovarian hyperstimulation
GnRH agonist
GnRH antagonist
In vitro fertilization
Meta-analysis
Systematic review
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
12
09
2020
accepted:
19
09
2020
pubmed:
3
3
2021
medline:
22
5
2021
entrez:
2
3
2021
Statut:
ppublish
Résumé
To evaluate the effectiveness and safety of long-acting GnRH agonist follicular and GnRH antagonist protocols among women undergoing in vitro fertilization (IVF) using data published in both English-language and Chinese studies. We systematically searched the PubMed, Embase, Cochrane, CNKI, and Wanfang databases up to March 2019 for studies comparing long-acting GnRH agonist follicular and GnRH antagonist protocols in women undergoing IVF. The primary outcome was live birth rate; secondary outcomes were clinical pregnancy rate and implantation rate; safety outcomes were ovarian hyperstimulation syndrome (OHSS) and miscarriage rate in fresh cycle. Statistical analysis was done using R software. The study protocol was registered with PROSPERO (CRD42019139396). In 11 studies that met the inclusion criteria, 1994 women belonged to the long-acting GnRH agonist follicular protocol group and 1678 to the GnRH antagonist protocol group. Live birth rate (relative risk (RR) 1.61; 95% confidence interval (CI) 1.27, 2.05; P < 0.001), clinical pregnancy rate (RR 1.44; 95% CI 1.32, 1.58; P < 0.001), and implantation rate (RR 1.58; 95% CI 1.44, 1.73; P = 0.001) were higher in the long-acting GnRH agonist follicular protocol compared with the antagonist protocol group. There was no difference in miscarriage rate (RR 0.98; 95% CI 0.58, 1.64; P = 0.98) between the long-acting GnRH agonist follicular and antagonist protocols. However, OHSS rate (RR 1.63; 95% CI 1.15, 2.32; P = 0.0058) was lower in the GnRH antagonist protocol compared to the long-acting GnRH agonist protocol group. The long-acting GnRH agonist follicular protocol was beneficial in improving live birth rate, clinical pregnancy rate, and implantation rate whereas the incidence of OHSS was significantly lower in women undergoing the GnRH antagonist protocol.
Identifiants
pubmed: 33651282
doi: 10.1007/s12325-020-01612-7
pii: 10.1007/s12325-020-01612-7
pmc: PMC8107074
doi:
Substances chimiques
Gonadotropin-Releasing Hormone
33515-09-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Pagination
2027-2037Références
Allahbadia GN. The ideal stimulation protocol: is there one? J Obstet Gynaecol India. 2015;65:357–61.
doi: 10.1007/s13224-015-0723-8
van den Wijngaard L, van Wely M, Dancet EAF, et al. Patients’ preferences for gonadotrophin-releasing hormone analogs in in vitro fertilization. Gynecol Obstet Investig. 2014;78:16–21.
doi: 10.1159/000362274
Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van de Koppel P, Collins JA. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil Steril. 1992;58:888–96.
doi: 10.1016/S0015-0282(16)55430-2
Shalev E, Leung PCK. Gonadotropin-releasing hormone and reproductive medicine. J Obstet Gynaecol Can. 2003;25:98–113.
doi: 10.1016/S1701-2163(16)30206-7
Geng Y, Xun Y, Hu S, Lai Q, Jin L. GnRH antagonist versus follicular-phase single-dose GnRH agonist protocol in patients of normal ovarian responses during controlled ovarian stimulation. Gynecol Endocrinol. 2019;35:309–13.
doi: 10.1080/09513590.2018.1528221
Surrey ES, Silverberg KM, Surrey MW, Schoolcraft WB. Effect of prolonged gonadotropin-releasing hormone agonist therapy on the outcome of in vitro fertilization-embryo transfer in patients with endometriosis. Fertil Steril. 2002;78:699–704.
doi: 10.1016/S0015-0282(02)03373-3
Ren J, Sha A, Han D, Li P, Geng J, Ma C. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment? Fertil Steril. 2014;102:75–81.
doi: 10.1016/j.fertnstert.2014.03.030
Lambalk CB, Banga FR, Huirne JA, et al. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type. Hum Reprod Update. 2017;23:560–79.
doi: 10.1093/humupd/dmx017
Albuquerque LET, Tso LO, Saconato H, Albuquerque MCRM, Macedo CR. Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database Syst Rev. 2013;CD002808.
Wang R, Lin S, Wang Y, Qian W, Zhou L. Comparisons of GnRH antagonist protocol versus GnRH agonist long protocol in patients with normal ovarian reserve: a systematic review and meta-analysis. PLoS One. 2017;12(4):e0175985.
Gordts S, Van Turnhout C, Campo R, Puttemans P, Valkenburg M, Gordts S. A prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF. Facts Views Vis ObGyn. 2012;4:82–7.
pubmed: 24753894
pmcid: 3987498
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
Clark HD, Wells GA, Huët C, et al. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials. 1999;20:448–52.
doi: 10.1016/S0197-2456(99)00026-4
Yang R, Luo L, Wang Y, et al. Clinical protocol selection in patients with polycystic ovary syndrome who undergone the first IVF/ICSI-ET treatment. Reprod Contracept. 2015;35:241–6.
Hu YQ, Cai JL, Liu LL, et al. Clinical outcomes of modified long protocol used in patients who failed in first cycle with antagonist protocol. Prog Obstet Gynecol. 2014;23:455–8.
Zhang Y, Bao JH, Yao HR, et al. Clinical application and economic analysis of gonadotropin-releasing hormone antagonist protocol in patients with decreased ovarian reserve. Reprod Contracept. 2018;38:228–31.
Liu N, Ma Y, Li R, et al. Comparison of follicular fluid amphiregulin and EGF concentrations in patients undergoing IVF with different stimulation protocols. Endocrine. 2012;42:708–16.
doi: 10.1007/s12020-012-9706-z
Zhao J. Clinical application analysis of long acting follicular-phase GnRH agonist versus GnRH antagonist protocol in patients with polycystic ovary syndrome undergoing controlled ovarian stimulation. Chin J Woman Child Health Res. 2017;28:430–1.
Xu DF, Wu QF. Application and effect of super long project and GnRH-antagnist in IVF-ET with the patients of PCOS. Jiangxi Med J. 2015;50:13–5.
Xu HL, Zheng BH, Qiu SM, et al. Selection of controlled ovarian hyperstimualtion in patients with polycystic ovary syndrome who undergone in vitro fertilization. Strait J Prev Med. 2017;23:94–6.
Liu L, Zhao YQ, Liu P, et al. The clinical analysis of GnRH antagonist protocols on PCOS patients. Ningxia Med J. 2015;37:818–20.
Tian LF, Wu QF, Su Q, et al. A pregnancy outcomes comparison of low ovarian response in infertile patients undergoing different controlled ovarian hyperstimulation protocols in IVF treatment. Jianxi Med J. 2013;48:479–82.
Zhao ZM, Hao GM, Cui N, et al. Impact of long protocol in early follicular phase of patients with polycystic ovary syndrome who undergone in vitro fertilizaton-embryo transfer on clinical outcomes. Chin J Fam Plan. 2018;26:709–13.
Daya S. Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. Cochrane Database Syst Rev. 2000;(2):CD001299.
Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: effect on hormonal levels and follicular development in in vitro fertilization cycles. J Clin Endocrinol Metab. 2003;88:5632–7.
doi: 10.1210/jc.2003-030805
Seow K-M, Lin Y-H, Hsieh B-C, et al. Characteristics of progesterone changes in women with subtle progesterone rise in recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonist cycle. Gynecol Obstet Investig. 2010;70:64–8.
doi: 10.1159/000290062
Bosch E, Valencia I, Escudero E, et al. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril. 2003;80:1444–9.
doi: 10.1016/j.fertnstert.2003.07.002
Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011;CD001750.
Braakhekke M, Kamphuis EI, Dancet EA, Mol F, van der Veen F, Mol BW. Ongoing pregnancy qualifies best as the primary outcome measure of choice in trials in reproductive medicine: an opinion paper. Fertil Steril. 2014;101:1203–4.
doi: 10.1016/j.fertnstert.2014.03.047
Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online. 2007;14:640–9.
doi: 10.1016/S1472-6483(10)61059-0
Xiao J, Su C, Zeng X. Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis. PLoS One. 2014;9:e106854.
doi: 10.1371/journal.pone.0106854
Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4:CD001750.